Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.
By H. Kantarjian, C. Sawyers, Andreas Hochhaus, F. Guilhot, C. Schiffer, C. Gambacorti-Passerini, D. Niederwieser, D. Resta, R. Capdeville, U. Zoellner and 22 more. New England Journal of Medicine, 2002
2,100 citations recorded by the source corpus.
Subfields: Genetics, Hematology, Rheumatology
View Paper: https://www.semanticscholar.org/paper/e7be5ab47379fd4e0c574744b41b0d3dc197c81d
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Genetics
- A. Jemal
- C. Ashby
- Andreas Hochhaus
- C. Sawyers
- Zhesheng Chen
- H. Kantarjian
- Brian J. Druker
- Y. Luqmani
In Hematology
- E. Scholar
- A. Arora
- C. Ashby
- Andreas Hochhaus
- Zhesheng Chen
- H. Kantarjian
- Brian J. Druker
- Y. Luqmani
In Rheumatology
Citations in the corpus
- Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. (2006, background): “…activity against certain systemic solid tumors, such as gastrointestinal stromal tumors (GIST), and chronic myelogenous leukemia (CML) may be in part a result of its antiangiogenic as well as its direct antitumor effects (Demetri et al., 2002; Kantarjian et al., 2002; Sawyers et al., 2002).”
- Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug (2002, background): “Subsequently, three large multinational studies have been carried out in 532 patients with late chronic-phase CML in whom previous interferon therapy had faile”
- Chemotherapy and the war on cancer (2005, background): “However, BCR–ABL translocation can still be detected by PCR analysis in cells of most patient”
- BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review. (2010, background): “Previous phase I and phase II clinical studies in CML patients esistant or intolerant to rIFN- confirmed its clinical efficacy and afety [38,63].”
- Annual report to the nation on the status of cancer, 1975–2001, with a special feature regarding survival (2004, background): “More recent advances include allogeneic bone marrow transplant and treatment with imatinib mesylate, which has been demonstrated to be highly effective in inducing and sustaining disease remission when used as a first course of treatment.(101,102) Survival improvements resulting from imatinib mesyla”
- Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. (2007, neutral): “Minimal 19 (10) 17 (13) 2 (3) 16 (9) 15 (12) 1 (2)”